Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus
AssigneeWyeth
InventorsJoseph P. Sabatucci, Craig E. Caufield, Alexander A. Greenfield, Schuyler Antane, Eamonn P. Morrison
Life of this patent
Estimating the term…
Abstract
This invention provides compounds of formula I, having the structure 1 wherein R1, R4, A, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.
Claims13
A compound of formula (I) having the structure
- 14
- wherein:
- Z is
- 15
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen, A is a bond;
- or
- 16
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
- 25
- wherein:
- Z is
- 26
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 27
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A method of modulating glucose levels in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
- 28
- wherein:
- Z is
- 29
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 30
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A method of treating or inhibiting type 11 diabetes in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
- 31
- wherein:
- Z is
- 32
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 33
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A method of treating primary hypertension in a mammal in need thereof, which comprises providing to said mammal a compound of formula (I) having the structure
- 34
- wherein:
- Z is
- 35
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 36
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A method of treating atherosclerosis in a mammal in need thereof, which comprises providing to said mammal a compound of formula (I) having the structure
- 37
- wherein:
- Z is
- 38
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 39
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof.
A phramaceutical composition which comprises a compound of formula (I) having the structure
- 40
- wherein:
- Z is
- 41
- Y is selected from O, S, N, C═C, or C═N;
- R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
- Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
- R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh;
- or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—;
- or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
- R4 is hydrogen or halogen,
- A is a bond;
- or
- 42
- wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
- R8 is hydrogen or alkyl of 1-6 carbon atoms;
- or a pharmaceutically acceptable salt form thereof, and a pharmaceutical carrier.
Dependencies are inferred from the claim text.